Human Sarcoma Growth Is Sensitive to Small-Molecule Mediated AXIN Stabilization
Figure 5
In vivo effects of SEN461 in HT-1080 xenograft model.
(A) Pharmacokinetics and pharmacodynamics of SEN461 in mice. Concentration of SEN461 in tumors (black line) and relative c-MYC human mRNA values (columns) in HT-1080 xenograft tumors at 1, 4 and 8 hours after 30 mpk BID oral administration of SEN461. The data are presented as mean ± SEM (n = 5) and T0 represents c-MYC human mRNA value at 1 hour after vehicle administration in the control group. (B) mRNA level for the human VEGFA gene in HT-1080 xenograft tumors at 1 hour after 30 mpk BID of SEN461. The data are presented as means ± SEM (n = 5). (C) Antitumor activity of SEN461 in a HT-1080 xenograft tumor model. Treatment groups (5 mice per group) received 30 mg/kg twice a day for seven consecutive days.